Humacyte Launches New Public Stock Offering, Signaling Further Dilution
HUMA has more than doubled off its 52-week low of $0.547.
Summary
Humacyte has commenced an underwritten public offering of common stock, with underwriters having an option to purchase an additional 15%. This follows shareholder approval on June 9th to increase authorized common stock by 200 million shares. The company has a history of dilutive financing, including a $20 million offering in March, and issued a going concern warning in its Q1 10-Q. This offering will likely result in significant dilution for existing shareholders as the company seeks capital for commercialization and pipeline development. The actual size and pricing of the offering will determine the exact dilutive impact.
At the time of this announcement, HUMA was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $297.5M. The 52-week trading range was $0.55 to $2.84. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.